AGTR1 – A1166C is a single-nucleotide polymorphism (SNP) found in the AGTR1 gene, which encodes the angiotensin II type 1 receptor (AT1R). This receptor mediates many of angiotensin II’s effects on blood vessels, salt handling and vascular tone. The A1166C change lies in a noncoding region that can influence RNA stability or regulatory interactions rather than altering the protein sequence. Identified in population and candidate-gene studies, A1166C has been examined for associations with blood-pressure–related traits, cardiac remodeling patterns, and variability in physiological responses. Mechanistic work has explored effects on receptor expression and microRNA binding, so the variant is mainly used as an inherited marker that complements biochemical and physiological measurements rather than as a standalone classification.

Reported presence of the C allele (often described as a higher 'signal' for this variant) has been associated in some studies with patterns of stronger angiotensin II signaling, and with population-level links to blood-pressure–related traits and cardiac structural differences. Such associations are probabilistic and vary by ancestry and study design. Low or absent C-allele status (A/A genotype) suggests the more common allele pattern in many groups and does not imply absence of cardiovascular risk factors. Interpretation requires the full Cardio Zoomer profile: genetic tendency is one piece of the puzzle that should be weighed alongside lipid patterns, inflammatory markers, endothelial function, metabolic data and clinical measures to understand overall cardiovascular biology.

Cardio Zoomer includes AGTR1 – A1166C to add inherited information about angiotensin II pathway tendencies. As a genetic marker of vascular signaling patterns, it helps providers contextualize blood-pressure–related findings and integrate pharmacogenomic and risk-pattern insights with biochemical markers to refine personalized prevention and monitoring strategies.